Blue Jet Healthcare has scheduled its 58th Annual General Meeting (AGM) for Monday, September 21, 2026, to be held through Video Conferencing or Other Audio Visual Means. The meeting aims to transact ordinary business, including the adoption of audited standalone financial statements for the financial year ended March 31, 2026, and special business concerning key management appointments.

The Board of Directors has recommended a final dividend of ₹1.20 per equity share for FY26. The record date for determining dividend entitlement is set for Monday, September 14, 2026. Shareholders holding securities as on this cut-off date will be eligible to participate in remote e-voting, which commences on Friday, September 18, 2026, and concludes on Sunday, September 20, 2026.

Key Agenda Items

The AGM notice outlines several critical resolutions requiring shareholder approval:

• Adoption of Financials: Members will receive, consider, and adopt the Audited Standalone Financial Statements for FY26, along with reports from the Board and Auditors.
• Director Re-appointment: Mr. Naresh Suryakant Shah is proposed for re-appointment as a Whole-Time Director, retiring by rotation.
• Auditor Re-appointment: M/s. KKC & Associates LLP is proposed for re-appointment as Statutory Auditors for a second term of five years, extending until the conclusion of the 63rd AGM in FY31.

Executive Leadership Renewal

A significant portion of the agenda involves the re-appointment of the company’s top leadership for five-year terms effective from April 13, 2027, to April 12, 2032.

Both appointments require approval via Special Resolution. The remuneration packages include basic salaries, house rent allowances, performance-linked incentives, medical benefits, and other statutory contributions. The Board has sought member consent to pay remuneration exceeding limits prescribed under Regulation 17(6)(e) of the SEBI Listing Regulations, if applicable during their tenure.

Voting and Participation Guidelines

Shareholders can cast votes electronically through the MUFG Intime India Private Limited platform. Those holding shares in demat mode may use NSDL or CDSL login methods, while physical shareholders must register via InstaVote. Corporate members are required to submit certified board resolutions authorizing representatives to vote.

The Company Secretary, Sweta Poddar, confirmed that the Annual Report and AGM Notice are available electronically on the company’s website. Shareholders are advised to update their KYC details with depositories to ensure timely receipt of dividends, which will be paid within thirty days of AGM approval.

Blue Jet Healthcare Limited reported a full-year revenue of ₹9,473 million for the financial year ended March 31, 2026 (FY26), marking an 8% decline from the previous year. The company’s Profit After Tax (PAT) fell 18.8% to ₹2,478 million, driven primarily by customer inventory destocking in its Pharma Intermediates and API segment and pricing pressures in the artificial sweeteners business.

Despite the revenue contraction, the company maintained robust profitability metrics. EBITDA stood at ₹2,941 million, representing a margin of 31%, while the PAT margin remained strong at 26%. The Managing Director noted that Q1 saw exceptional momentum with revenue surging 118% year-on-year to ₹355 million, but this was followed by a sharp moderation in Q2 and Q3 as customers normalized their inventory levels. Q4 marked a recovery, with revenue rising 22% quarter-on-quarter to ₹235 million.

Financial Highlights

*Figures derived from disclosed percentage changes or prior year disclosures where available.

Strategic Investments and Capital Raise

The company successfully raised ₹8,000 million through the allotment of 15,810,276 equity shares under a Qualified Institutional Placement (QIP) on July 9, 2026. This capital infusion strengthens the balance sheet, which closed FY26 with approximately ₹350 million in liquid financial assets and zero debt. Operating cash flow for the year stood at ₹334 million.

Blue Jet Healthcare is actively expanding its manufacturing footprint. The company entered into an agreement to purchase a 102.48-acre industrial land parcel in Andhra Pradesh for ₹435.02 million to set up a new manufacturing facility. Additionally, the backward integration project at its Mahad facility is progressing well, aimed at reducing dependence on external raw material sources. A new R&D centre in Hyderabad, focusing on GLP-1 intermediates and peptide chemistry, has also been secured on lease.

Dividend and Corporate Governance

The Board of Directors recommended a final dividend of ₹1.20 per equity share for FY26, subject to shareholder approval at the 58th Annual General Meeting (AGM). The AGM is scheduled to be held on September 21, 2026, via Video Conferencing/Other Audio-Visual Means (OAVM).

Key corporate actions include the re-appointment of Mr. Naresh Suryakant Shah as Whole-Time Director and the re-appointment of M/s. KKC & Associates LLP as Statutory Auditors for a second term of five years. The Board also approved the re-appointment of Executive Chairman Mr. Akshay Bansarilal Arora and Managing Director Mr. Shiven Akshay Arora for further terms commencing April 13, 2027.

What the Numbers Show

While top-line revenue contracted by 8%, the company’s EBITDA margin held steady at 31%, indicating that cost structures remained resilient despite volume headwinds in key segments. The significant drop in PAT (18.8%) relative to the revenue decline suggests a disproportionate impact from specific segment underperformance, particularly in Pharma Intermediates and APIs, rather than broad-based operational inefficiencies. The debt-free status and substantial cash reserves provide a strong buffer for ongoing capex commitments, including the ₹1,000 crore planned investment in the Vizag greenfield facility.